Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
25.2
% (year-on-year change in operating income)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales71,380million yenYear on year +9.6%Progress 23.5%
Operating profit6,519million yenYear on year +25.2%Progress 20.4%
Ordinary income7,941million yenYear on year +100.9%Progress 26.5%
Net income attributable to owners of the parent5,531million yenYear on year +120.1%Progress 25.7%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥112.36
Financial position at period-end
Total assets480,709million yen
of which net assets 182,476 million yenEquity ratio 38.0%vs. prior year-end +0.5pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+729
Investment-3,302
Financials-346
Net change-2,919
Stacked from zero: upward is an increase in cash, downward a decrease (in million yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period41,724 million yen
Segment revenueDomestic 55,981 million yen (YoY +6.1%), Overseas expansion 15,612 million yen (YoY +25.0%)
Segment profitDomestic 7,013 million yen (YoY +2.0%), Overseas expansion 5 million yen
Outlook and shareholder returns
Full-year earnings forecast
Net Sales304,000 million yen (YoY +11.1%)
Operating profit32,000 million yen (YoY +38.5%)
Ordinary income30,000 million yen (YoY +6.8%)
Net income21,500 million yen (YoY +309.5%)
Annual Dividend Forecast¥80 (common shares) → ¥85 (common shares)（+6.3%）
Factors Behind Changes in Business Performance
Increased sales volume and unit prices, higher sales in Towa INT's European B2C and European B2B businesses, offsetting the deterioration in 三生医薬's performance, and a ¥1,424 million gain on valuation of derivatives
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Material subsequent eventsIn July 2026, an announcement was made concerning the acquisition of shares in 田辺ファーマファクトリー株式会社 from 田辺ファーマ株式会社 and the succession of its manufacturing and marketing authorization.
Impairment lossNone recorded (there were no applicable matters concerning impairment losses on property, plant and equipment or other assets for each reporting segment)
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets 2 million yen / Extraordinary loss Losses on disposal of fixed assets 0 million yen
Depreciation and amortization4,553 million yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for analysts and institutional investors)
Issued Shares at Period-End51,516,000
Treasury Shares at Period-End2,288,133
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | 71,380 million yen (YoY +9.6%) |
| Operating profit | 6,519 million yen (YoY +25.2%) |
| Ordinary income | 7,941 million yen (YoY +100.9%) |
| Profit attributable to owners of the parent | 5,531 million yen (YoY +120.1%) |
| Net income per share | ¥112.36 |
| Equity ratio | End of the current fiscal period 38 / End of previous period 37.5 |
| Total assets | 480,709 million yen |
| Net assets | 182,476 million yen |
| Cash flows from operating activities | 729 million yen |
| Cash flows from investing activities | -3,302 million yen |
| Cash flows from financing activities | -346 million yen |
| Cash and cash equivalents at end of period | 41,724 million yen |
| Full-year earnings forecast | Net Sales 304,000 million yen (YoY +11.1%) / Operating profit 32,000 million yen (YoY +38.5%) / Ordinary income 30,000 million yen (YoY +6.8%) / Net income 21,500 million yen (YoY +309.5%) |
| Annual Dividend Forecast | ¥80 (common shares) → ¥85 (common shares)（+6.3%） |
| Segment revenue | Domestic 55,981 million yen (YoY +6.1%), Overseas expansion 15,612 million yen (YoY +25.0%) |
| Segment profit | Domestic 7,013 million yen (YoY +2.0%), Overseas expansion 5 million yen |
| Depreciation and amortization | 4,553 million yen |
| Impairment loss | None recorded (there were no applicable matters concerning impairment losses on property, plant and equipment or other assets for each reporting segment) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets 2 million yen / Extraordinary loss Losses on disposal of fixed assets 0 million yen |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | In July 2026, an announcement was made concerning the acquisition of shares in 田辺ファーマファクトリー株式会社 from 田辺ファーマ株式会社 and the succession of its manufacturing and marketing authorization. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 51,516,000 |
| Treasury Shares at Period-End | 2,288,133 |
| Factors Behind Changes in Business Performance | Increased sales volume and unit prices, higher sales in Towa INT's European B2C and European B2B businesses, offsetting the deterioration in 三生医薬's performance, and a ¥1,424 million gain on valuation of derivatives |
Items this document does not state (6)
Operating MarginRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in both sales volume and unit prices, together with higher sales in Towa INT's European B2C and European B2B businesses, offset the deterioration in 三生医薬's performance. Ordinary income also benefited from a ¥1,424 million gain on valuation of derivatives.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.